Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1950 1
1951 2
1952 1
1954 1
1955 1
1956 1
1957 1
1958 2
1960 1
1961 1
1962 1
1967 1
1975 1
1976 1
1979 2
1981 2
1982 1
1984 1
1989 1
1990 2
1991 3
1993 2
1994 1
1995 1
1996 1
1997 1
1999 1
2000 3
2002 4
2003 1
2004 3
2005 3
2006 6
2007 2
2008 3
2009 1
2010 3
2011 9
2012 4
2013 6
2014 6
2015 12
2016 5
2017 9
2018 10
2019 11
2020 16
2021 11
2022 15
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. Concin N, et al. Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18. Int J Gynecol Cancer. 2021. PMID: 33397713 Free article.
Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly decided to u …
Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological O …
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Holmes J, Howitt BE, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Aggarwal S. Abu-Rustum N, et al. J Natl Compr Canc Netw. 2023 Feb;21(2):181-209. doi: 10.6004/jnccn.2023.0006. J Natl Compr Canc Netw. 2023. PMID: 36791750
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new …
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of …
Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/beta-catenin signaling activation (Review).
Katoh M. Katoh M. Int J Mol Med. 2018 Aug;42(2):713-725. doi: 10.3892/ijmm.2018.3689. Epub 2018 May 17. Int J Mol Med. 2018. PMID: 29786110 Free PMC article. Review.
beta-catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E-cadherin/CDH1, N-cadherin/CDH2, VE-cadherin/CDH5 and alpha-catenins), transmembrane-type mucins (MUC1/CD227 and MUC16/CA125), signaling regulators (APC, AXIN1, AXIN2 and NHERF1/EBP5 …
beta-catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E-cadherin/CDH1, N-cadherin/CDH2, VE-cadher …
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, Arun B, Buys SS, Cheng H, Domchek SM, Friedman S, Giri V, Goggins M, Hagemann A, Hendrix A, Hutton ML, Karlan BY, Kassem N, Khan S, Khoury K, Kurian AW, Laronga C, Mak JS, Mansour J, McDonnell K, Menendez CS, Merajver SD, Norquist BS, Offit K, Rash D, Reiser G, Senter-Jamieson L, Shannon KM, Visvanathan K, Welborn J, Wick MJ, Wood M, Yurgelun MB, Dwyer MA, Darlow SD. Daly MB, et al. J Natl Compr Canc Netw. 2023 Oct;21(10):1000-1010. doi: 10.6004/jnccn.2023.0051. J Natl Compr Canc Netw. 2023. PMID: 37856201
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, …
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/l …
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM. Hamilton CA, et al. Gynecol Oncol. 2021 Mar;160(3):817-826. doi: 10.1016/j.ygyno.2020.12.021. Epub 2021 Jan 27. Gynecol Oncol. 2021. PMID: 33516529 Review.
INTRODUCTION: In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical management, …
INTRODUCTION: In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment …
Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gadducci A, Multinu F, De Vitis LA, Cosio S, Carinelli S, Aletti GD. Gadducci A, et al. Gynecol Oncol. 2023 Apr;171:95-105. doi: 10.1016/j.ygyno.2023.02.009. Epub 2023 Feb 24. Gynecol Oncol. 2023. PMID: 36842409 Review.
Endometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning endometrium. ...The aim of this review is to assess the clinical, pathological, and biological features and the therapeutic options f …
Endometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning …
Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer.
Ryu KJ, Kim MS, Lee JY, Nam S, Jeong HG, Kim T, Park H. Ryu KJ, et al. JAMA Netw Open. 2022 Nov 1;5(11):e2243951. doi: 10.1001/jamanetworkopen.2022.43951. JAMA Netw Open. 2022. PMID: 36441547 Free PMC article.
IMPORTANCE: The association of tamoxifen use with the risk of uterine diseases, such as endometrial cancer, in premenopausal women with breast cancer remains controversial. However, many studies have reported an increased risk of uterine disease among …
IMPORTANCE: The association of tamoxifen use with the risk of uterine diseases, such as endometrial cancer, in premenopausal w …
Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
Pasqual E, Schonfeld S, Morton LM, Villoing D, Lee C, Berrington de Gonzalez A, Kitahara CM. Pasqual E, et al. J Clin Oncol. 2022 May 1;40(13):1439-1449. doi: 10.1200/JCO.21.01841. Epub 2022 Jan 19. J Clin Oncol. 2022. PMID: 35044839 Free PMC article.
PURPOSE: Since the 1980s, both the incidence of differentiated thyroid cancer (DTC) and use of radioactive iodine (RAI) treatment increased markedly. ...Risks of total solid and female breast cancer, the most common cancer type, were highest among 20-year DTC …
PURPOSE: Since the 1980s, both the incidence of differentiated thyroid cancer (DTC) and use of radioactive iodine (RAI) treatment inc …
SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, Miyamoto JB, Nesterova A, Westendorf L, Van Epps HA, Whiting N, Benjamin DR. Sussman D, et al. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. doi: 10.1158/1535-7163.MCT-13-0896. Epub 2014 Sep 24. Mol Cancer Ther. 2014. PMID: 25253783
In addition to breast cancer, other indications showing LIV-1 expression include melanoma, prostate, ovarian, and uterine cancer. ...These results support the clinical evaluation of SGN-LIV1A as a novel therapeutic agent for patients with LIV-1-express …
In addition to breast cancer, other indications showing LIV-1 expression include melanoma, prostate, ovarian, and uterine c …
The Effect of Pelvic Floor Muscle Interventions on Pelvic Floor Dysfunction After Gynecological Cancer Treatment: A Systematic Review.
Brennen R, Lin KY, Denehy L, Frawley HC. Brennen R, et al. Phys Ther. 2020 Aug 12;100(8):1357-1371. doi: 10.1093/ptj/pzaa081. Phys Ther. 2020. PMID: 32367126
The results provided moderate-level evidence that pelvic floor muscle training with counseling and yoga or core exercises were beneficial for sexual function (standardized mean difference = -0.96, 95% CI = -1.22 to -0.70, I2 = 0%) and health-related quality of life (standardized …
The results provided moderate-level evidence that pelvic floor muscle training with counseling and yoga or core exercises were beneficial fo …
179 results